CD25 CD122 CD132 Reporter Cell Line

Description

Interleukin-2 (IL-2) is a key growth factor for tumor-infiltrating lymphocytes, mainly expressed by activated T cells during recognition of homologous antigens. While IL-2 promotes the proliferation and survival of activated effector cells and naive T cells, it also activates regulatory T cells (Tregs).The activity of IL-2 primarily occurs through binding to IL-2 receptors on the surface of lymphocytes and transmitting signals intracellularly. The IL-2 receptor is a heterotrimer composed of α, β, and γ subunits (IL-2Rα/CD25, IL-2Rβ/CD122, IL-2Rγ/CD132).IL-2Rγ/CD132 is expressed on all lymphocytes, while IL-2Rβ/CD122 is constitutively expressed on natural killer (NK) cells and CD8 memory T cells and can be induced on naive T cells post-antigen recognition. IL-2Rγ/CD132 and IL-2Rβ/CD122 are subunits capable of intracellular signal transduction, whereas IL-2Rα/CD25 does not participate in signal transduction.At low concentrations, IL-2 preferentially binds to high-affinity trimeric complex receptors (IL2Rαβγ) expressed on Tregs, thus low-dose IL-2 can activate Tregs to induce immune tolerance, used in treating autoimmune diseases like Type 1 diabetes and lupus. High concentrations of IL-2 saturate Tregs and then bind to moderate-affinity dimeric complex receptors (IL2Rβγ) expressed on NK cells and CD8+ T cells, activating them and increasing anti-cancer activity. When IL-2Rα/CD25 subunit is present alone, its affinity for IL-2 is only one percent of the trimeric complex receptor (IL2Rαβγ). Therefore, different research companies have explored various design approaches based on different application scenarios, including PEG modification, Fc fusion, mutant design, bispecific antibody design, and combination immunotherapy checkpoint antibody strategies.AcceGen has developed CD122 CD132 Reporter Cell Line/GM-C29054 reporter cell line that does not express IL-2Rα/CD25 receptor and CD25 CD122 CD132 Reporter Cell Line/GM-C29055 reporter cell line with high expression of IL-2Rα/CD25 receptor. Upon IL-2 binding to the receptor, downstream signal pathways are activated, thereby inducing the expression of luciferase. Luciferase readouts represent the activation effect of the signal pathway, making it suitable for in vitro evaluation of IL-2 and its receptor-related drugs.